Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Pretreatment for Pegloticase Re-challenge in Gout
NCT06186219Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in gout, sponsored by University of California, Los Angeles. Primary endpoints: Frequency and grade of adverse events at 2 years and Neutralizing antibody titers at Week 26. Started Apr 2024; status: completed.
02
Drugs
rituximab
03
Conditions
gout
Beyond the preview
Go deeper on NCT06186219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186219.